Free Trial
LON:OKYO

OKYO Pharma (OKYO) Share Price, News & Analysis

GBX 1.40
-0.45 (-24.32%)
(As of 05/19/2023)
Today's Range
1.40
1.98
50-Day Range
1.40
1.40
52-Week Range
1.35
8.50
Volume
364,142 shs
Average Volume
431,999 shs
Market Capitalization
£23.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
OKYO stock logo

About OKYO Pharma Stock (LON:OKYO)

OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.

OKYO Stock Price History

OKYO Stock News Headlines

OKYO Pharma Says Phase 2 Study Of OK-101 Did Not Meet Primary Goal
Eyepoint Pharmaceuticals stock soars on wet-AMD trial results
OKYO Pharma raises $5.84m via share issuance
OKYO Pharma phase II dry eye trial making encouraging progress
See More Headlines
Receive OKYO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OKYO Pharma and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
6
Year Founded
N/A

Profitability

Net Income
£-6,700,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Cash Flow
GBX 0.05 per share
Book Value
GBX (1) per share

Miscellaneous

Outstanding Shares
1,660,000,000
Free Float
N/A
Market Cap
£23.24 million
Optionable
Not Optionable
Beta
-0.06
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Dr. Gary S. Jacob Ph.D. (Age 75)
    CEO & Exec. Director
    Comp: $311k
  • Mr. Michael Paul Beck (Age 65)
    Founder
  • Ms. Keeren Shah (Age 45)
    Chief Financial Officer
  • Dr. Rajkumar Patil Ph.D. (Age 64)
    Chief Scientific Officer

OKYO Stock Analysis - Frequently Asked Questions

How have OKYO shares performed in 2024?

OKYO Pharma's stock was trading at GBX 1.40 at the beginning of 2024. Since then, OKYO shares have increased by 0.0% and is now trading at GBX 1.40.
View the best growth stocks for 2024 here
.

How do I buy shares of OKYO Pharma?

Shares of OKYO stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:OKYO) was last updated on 5/22/2024 by MarketBeat.com Staff

From Our Partners